Can GLP-1 drugs treat addiction?

This episode of Science Friday explores the emerging evidence that GLP-1 drugs—originally developed for diabetes and weight management—may have potential in treating alcohol and substance use disorders. The conversation begins with a listener’s story: Brian from Wisconsin, who noticed an immediate and dramatic reduction in his alcohol cravings after starting a GLP-1 medication for diabetes. This anecdotal experience has sparked scientific interest, leading researchers like Dr. Joseph Schacht to conduct clinical trials on GLP-1 agonists for alcohol use disorder. While preclinical studies and electronic health record analyses suggest a consistent link between GLP-1 use and reduced substance use, clinical trial results remain mixed, with one small study showing reduced cravings and consumption, but larger, more rigorous trials still pending. Experts caution that while these drugs may dampen the desire to drink by affecting brain circuits tied to craving and reward, they are not a standalone solution. Sarah Karstens emphasizes the importance of addressing the emotional, environmental, and psychological roots of addiction, warning that removing a coping mechanism without replacement could be harmful. The episode also raises concerns about stigma, access, and long-term risks like malnutrition, especially in vulnerable populations. Ultimately, the discussion suggests a possible 'final common pathway' in the brain’s reward system that underlies both overeating and addiction, pointing to a deeper biological unity in compulsive behaviors.